916653-46-8

Upstream product

• 3058-39-7 4-iodobenzonitrile 
• 223463-13-6 2-iodo-5-bromopyridine 
• 624-28-2 2,5-dibromopyridine 
• 171364-82-2 4-cyanophenylboronic acid pinacol ester 
• 126747-14-6 4-cyanophenylboronic acid 

Relevant academic research and scientific papers

Discovery of 5-(2-chloro-4′-(1H-imidazol-1-yl)-[1,1′-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD

Endogenous nitrosothiols (SNOs) including S-nitrosoglutathione (GSNO) serve as reservoir for bioavailable nitric oxide (NO) and mediate NO-based signaling, inflammatory status and smooth muscle function in the lung. GSNOR inhibition increases pulmonary GS

Tertiary amine derivatives and organic electroluminescent device including the same

Provided is a tertiary amine derivative which contributes to a substantial increase in service life of an organic electroluminescent device by minimizing damages to organic matter inside the organic electroluminescent device via effective absorption of a high-energy external light source in the UV region. According to the present invention, the organic electroluminescent device comprises: a first electrode and a second electrode; and one or more organic material layers disposed between the first electrode and the second electrode, wherein the organic material layers comprise a tertiary amine derivative represented by chemical formula 1. In the chemical formula 1, Z_1, Z_2, and Z_3 are each independently O or S.COPYRIGHT KIPO 2020

IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present disclosure is directed to compounds of formula (Ie) and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, m, n, X1, X2, X3 and X4 are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

Fluoranthene derivative and organic electroluminescent device including the same

Provided are a fluoranthene derivative represented by chemical formula 1 and an organic electroluminescent device comprising the same. In the chemical formula 1, definition of each substituent is as defined in the detailed description of the present invention. The organic electroluminescent device comprises: a first electrode; a second electrode; and one or more organic films disposed between the electrodes, wherein the organic films comprise the fluoranthene derivative.(AA) Negative electrode(BB) Electron injection layer(CC) Electron transport layer(DD) Light emitting layer(EE) Hole transport layer(FF) Hole injection layer(GG) Positive electrode(HH) Organic filmCOPYRIGHT KIPO 2016

Pentamidine analogs as inhibitors of [3H]MK-801 and [3H]ifenprodil binding to rat brain NMDA receptors

The anti-protozoal drug pentamidine is active against opportunistic Pneumocystis pneumonia, but in addition has several other biological targets, including the NMDA receptor (NR). Here we describe the inhibitory potencies of 76 pentamidine analogs at 2 bi

5-Bromo-2-pyridylzinc reagent; Direct preparation and its coupling reactions

A facile synthetic route to the direct preparation of 5-bromo-2-pyridylzinc iodide has been developed. Treatment of 5-bromo-2-iodopyridine with active zinc gave rise to the selective oxidative addition to C-I bond under mild conditions. The resulting orga

Linear dicationic terphenyls and their aza analogues as antiparasitic agents

Novel dicationic terphenyl compounds and their aza analogues. Methods for combating microbial infections with novel dicationic terphenyl compounds and their aza analogues. Processes for synthesizing novel dicationic terphenyl compounds and their aza analo

HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE

Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.